Login to Your Account

Revised Desmoteplase Deal Could Earn Paion $102M

By Cormac Sheridan

Wednesday, January 2, 2008
Paion AG got its stroke drug desmoteplase back on track by signing a new agreement with its existing partner H. Lundbeck A/S, under which the latter firm will take on future development and global commercialization responsibility for the compound. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription